OBJECTIVES: Pancreatic ductal adenocarcinoma (PDAC) is often accompanied by weight loss. We sought to characterize factors associated with weight loss and observed nutritional interventions, as well as define the effect of weight loss on survival. METHODS: Consecutive subjects diagnosed with PDAC (N = 123) were retrospectively evaluated. Univariate analysis was used to compare subjects with and without substantial (>5%) weight loss. Multivariate logistic regression was performed to identify factors associated with weight loss, and survival analyses were performed using Kaplan-Meier curves and Cox survival models. RESULTS: Substantial weight loss at diagnosis was present in 71.5% of subjects and was independently associated with higher baseline body mass index, longer symptom duration, and increased tumor size. Recommendations for nutrition consultation and pancreatic enzyme replacement therapy occurred in 27.6% and 36.9% of subjects, respectively. Weight loss (>5%) was not associated with worse survival on multivariate analysis (hazard ratio, 1.32; 95% confidence interval, 0.76-2.30), unless a higher threshold (>10%) was used (hazard ratio, 1.77; 95% confidence interval, 1.09-2.87). CONCLUSIONS: Despite the high prevalence of weight loss at PDAC diagnosis, there are low observed rates of nutritional interventions. Weight loss based on current criteria for cancer cachexia is not associated with poor survival in PDAC.
OBJECTIVES:Pancreatic ductal adenocarcinoma (PDAC) is often accompanied by weight loss. We sought to characterize factors associated with weight loss and observed nutritional interventions, as well as define the effect of weight loss on survival. METHODS: Consecutive subjects diagnosed with PDAC (N = 123) were retrospectively evaluated. Univariate analysis was used to compare subjects with and without substantial (>5%) weight loss. Multivariate logistic regression was performed to identify factors associated with weight loss, and survival analyses were performed using Kaplan-Meier curves and Cox survival models. RESULTS: Substantial weight loss at diagnosis was present in 71.5% of subjects and was independently associated with higher baseline body mass index, longer symptom duration, and increased tumor size. Recommendations for nutrition consultation and pancreatic enzyme replacement therapy occurred in 27.6% and 36.9% of subjects, respectively. Weight loss (>5%) was not associated with worse survival on multivariate analysis (hazard ratio, 1.32; 95% confidence interval, 0.76-2.30), unless a higher threshold (>10%) was used (hazard ratio, 1.77; 95% confidence interval, 1.09-2.87). CONCLUSIONS: Despite the high prevalence of weight loss at PDAC diagnosis, there are low observed rates of nutritional interventions. Weight loss based on current criteria for cancer cachexia is not associated with poor survival in PDAC.
Authors: Thomas Pausch; Werner Hartwig; Ulf Hinz; Thomas Swolana; Bogota D Bundy; Thilo Hackert; Lars Grenacher; Markus W Büchler; Jens Werner Journal: Surgery Date: 2012-07-06 Impact factor: 3.982
Authors: Lola Rahib; Benjamin D Smith; Rhonda Aizenberg; Allison B Rosenzweig; Julie M Fleshman; Lynn M Matrisian Journal: Cancer Res Date: 2014-06-01 Impact factor: 12.701
Authors: Kenneth Fearon; Florian Strasser; Stefan D Anker; Ingvar Bosaeus; Eduardo Bruera; Robin L Fainsinger; Aminah Jatoi; Charles Loprinzi; Neil MacDonald; Giovanni Mantovani; Mellar Davis; Maurizio Muscaritoli; Faith Ottery; Lukas Radbruch; Paula Ravasco; Declan Walsh; Andrew Wilcock; Stein Kaasa; Vickie E Baracos Journal: Lancet Oncol Date: 2011-02-04 Impact factor: 41.316
Authors: Jeannine Bachmann; Mathias Heiligensetzer; Holger Krakowski-Roosen; Markus W Büchler; Helmut Friess; Marc E Martignoni Journal: J Gastrointest Surg Date: 2008-03-18 Impact factor: 3.452
Authors: Carla M M Prado; Jessica R Lieffers; Linda J McCargar; Tony Reiman; Michael B Sawyer; Lisa Martin; Vickie E Baracos Journal: Lancet Oncol Date: 2008-06-06 Impact factor: 41.316
Authors: Edmée C M Sikkens; Djuna L Cahen; Casper van Eijck; Ernst J Kuipers; Marco J Bruno Journal: J Gastrointest Surg Date: 2012-06-19 Impact factor: 3.452
Authors: Jonathan J Hue; Kavin Sugumar; Ravi K Kyasaram; John Shanahan; Joshua Lyons; Lee M Ocuin; Luke D Rothermel; Jeffrey M Hardacre; John B Ammori; Goutham Rao; Jordan M Winter; Sarah C Markt Journal: Ann Surg Oncol Date: 2021-04-09 Impact factor: 5.344
Authors: Peter Madril; Paige Golian; Marcia Nahikian-Nelms; Alice Hinton; Philip A Hart; Kristen M Roberts Journal: Pancreas Date: 2022-01-01 Impact factor: 3.243
Authors: William Paul Skelton; Hiral Parekh; Jason S Starr; Jose Trevino; Jessica Cioffi; Steven Hughes; Thomas J George Journal: J Gastrointest Cancer Date: 2018-03
Authors: John Bliton; Michael Parides; Peter Muscarella; John C McAuliffe; Katia Papalezova; Haejin In Journal: J Surg Res Date: 2020-12-09 Impact factor: 2.192
Authors: Erin E Talbert; Heather L Lewis; Matthew R Farren; Mitchell L Ramsey; Jeffery M Chakedis; Priyani Rajasekera; Ericka Haverick; Angela Sarna; Mark Bloomston; Timothy M Pawlik; Teresa A Zimmers; Gregory B Lesinski; Phil A Hart; Mary E Dillhoff; Carl R Schmidt; Denis C Guttridge Journal: J Cachexia Sarcopenia Muscle Date: 2018-01-07 Impact factor: 12.910